Asia Medical & Agricultural Laboratory & Research Center PCL (AMARC) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Asia Medical & Agricultural Laboratory & Research Center PCL THB 9.47, price THB 3.00, upside +215.7%, quality 80 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Asia Medical & Agricultural Laboratory & Research Center PCL for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
47‑month range 1.01 THB – 4.92 THB · fair‑value band 5.49 THB – 14.49 THB · the 3.00 THB price screens below the 9.47 THB fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Asia Medical & Agricultural Laboratory & Research Center PCL in your weekly email
Every Wednesday you see whether Asia Medical & Agricultural Laboratory & Research Center PCL is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Asia Medical and Agricultural Laboratory and Research Center Public Company Limited provides scientific services for the agriculture, food, pharmaceutical, and environment industries in Thailand.
Show more
Asia Medical and Agricultural Laboratory and Research Center Public Company Limited provides scientific services for the agriculture, food, pharmaceutical, and environment industries in Thailand. The company offers one stop and customized services, and quality, contaminants, additive services for meat and meat products, fats and oils, pet food, feedstuffs and feed raw materials, aquaculture aquatic animals and aquatic animal products, crops, foods, beverages, nutrition label, product shelf life, food contact materials, water ice, potable water, and utility water. It also provides fertilizer, hazardous substances, and research and development services for fertilizer, hazardous substance used in agriculture, soil, and water, as well as efficacy and residue testing of pesticide; testing and analyzing the quality of modern drugs, cannabis, hemp, herbs, and cosmetics; and checks the quality of water for consumption, production process water, and wastewater, as well as soil and air. In addition, the company offers calibration of instruments and equipment, including electrical and temperature, chemical, and mechanical metrology, as well as medical devices comprising electrocardiograph, non-invasive blood pressure monitor, patient monitor, oximeter pulse, and electrical safety analyzer; and inspection and certification for farming and agriculture, food processing and manufacturing, and environment. Further, it provides consultation and training services for laboratory quality management system, food sanitation, good food production standards, reporting calibration results of instrument and equipment, and standard systems. The company was founded in 2004 and is headquartered in Bangkok, Thailand. Asia Medical and Agricultural Laboratory and Research Center Public Company Limited is a subsidiary of Ladprao General Hospital Public Company Limited.
Stock analysis
Asia Medical & Agricultural Laboratory & Research Center PCL (AMARC) currently trades at 3.00 THB, while our model-based Fair Value estimate is 9.47 THB, implying the stock looks roughly 68.3% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 11.15 THB per share, and 24 of the 26 models we run sit above the 3.00 THB price.
Bear case: the Asset-Based group reads lowest at 0.9900 THB, and 2 of the 26 models stay below the price. Evidence for this calculation is low.
Scenario range: 5.49 THB (bear) to 14.49 THB (bull), the price of 3.00 THB sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 80/100 (high quality), in the Technology sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Asia Medical & Agricultural Laboratory & Research Center PCL reported revenue of 491M THB in FY2025 versus 246M THB in FY2021, a compound +18.9%/yr. Reported net income was 159M THB in FY2025, compounding +58.9%/yr from FY2021.
Key figures
Market cap 1.4B THB (≈ $42.4M) · P/E ratio 7.9 · P/S ratio 2.55 · EPS (TTM) 0.3800 THB · Dividend yield 8.3% · Net margin 32.3% · Return on equity 27.4% · Return on assets (EBIT) 8.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).
What moves the price
The share trades about 39% below its 52-week high and 41% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Technology peers we cover trades at −34% fair-value upside, at 216%, AMARC screens cheaper than that median.
Fair Value models
Bear 5.49 THBFair Value 9.47 THBBull 14.49 THB
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.0955 THB per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+42.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.4%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.0%
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in THB (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in THB: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+13.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+4.7%
Dividend (yield on the price)8.3%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.15% → 32%
2025 sits 750% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
⚠ Revenue per share shrinking 13.0%/yr over ~5Y (margins intact) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−6.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Thailand: IMF forecast 1.2% a year to 2030, 1.1% from 2016 to 2025) that is about −7.8% a year for the price.
Compare Asia Medical & Agricultural Laboratory & Research Center PCL with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Scientific & Technical Instruments · 160 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Asia Medical & Agricultural Laboratory & Research Center PCL Fair Value". https://www.fairvalue-calculator.com/stock/AMARC
Frequently asked questions
Is Asia Medical & Agricultural Laboratory & Research Center PCL (AMARC) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 9.47 THB versus a price of 3.00 THB, about +216% upside (undervalued).
What is the fair value of AMARC?
Our model-based fair value for Asia Medical & Agricultural Laboratory & Research Center PCL is 9.47 THB (as of Sep 24, 2026), built from audited fundamentals. The current price: 3.00 THB.
What is the quality score of AMARC?
Asia Medical & Agricultural Laboratory & Research Center PCL has a Quality Score of 80/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Asia Medical & Agricultural Laboratory & Research Center PCL (AMARC)?
Our model-based price target is the fair value of 9.47 THB (as of Sep 24, 2026) from 26 valuation models. Cautious scenario 5.49 THB, optimistic scenario 14.49 THB. It is a calculation from audited fundamentals, not an analyst target.
What is the Asia Medical & Agricultural Laboratory & Research Center PCL stock forecast for 2026?
Our models put fair value at 9.47 THB, about +216% upside versus a price of 3.00 THB (undervalued). Cautious scenario 5.49 THB, optimistic scenario 14.49 THB. The calculation is refreshed regularly with new filings.
What is the revenue of Asia Medical & Agricultural Laboratory & Research Center PCL (AMARC)?
Asia Medical & Agricultural Laboratory & Research Center PCL reported trailing-twelve-month revenue of about 497M THB (latest available figure, as of Sep 24, 2026).
Does Asia Medical & Agricultural Laboratory & Research Center PCL pay a dividend?
Asia Medical & Agricultural Laboratory & Research Center PCL currently shows a dividend yield of about 8.33% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Asia Medical & Agricultural Laboratory & Research Center PCL (AMARC)?
For today's price to be fair in a discounted-cash-flow model, Asia Medical & Agricultural Laboratory & Research Center PCL would have to grow free cash flow by -6.7 % per year for five years (discount rate 10.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +17.5 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of AMARC use?
Our models discount Asia Medical & Agricultural Laboratory & Research Center PCL at 10.1 %: a base by market capitalisation (nano), damped by beta 0.44, country premium for Thailand. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Asia Medical & Agricultural Laboratory & Research Center PCL that is -6.7 % per year a year over ten years, using the same discount rate (10.1 %) and the same formula as our fair value.
How much growth has Asia Medical & Agricultural Laboratory & Research Center PCL (AMARC) delivered so far?
Over the past 5 years revenue at Asia Medical & Agricultural Laboratory & Research Center PCL grew +17.5 % a year. The price currently implies -6.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Asia Medical & Agricultural Laboratory & Research Center PCL (AMARC) growing?
The median revenue growth in the sector is +8.2 % a year. That is the yardstick for the growth priced into Asia Medical & Agricultural Laboratory & Research Center PCL (-6.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Asia Medical & Agricultural Laboratory & Research Center PCL (AMARC)?
The free-cash-flow yield on the price is 12.64 %: that much free cash flow Asia Medical & Agricultural Laboratory & Research Center PCL produces per unit of market value. When it exceeds the discount rate of our models (10.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Asia Medical & Agricultural Laboratory & Research Center PCL (AMARC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Asia Medical & Agricultural Laboratory & Research Center PCL it is 9.47 THB per share (as of Sep 24, 2026), against a price of 3.00 THB. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Asia Medical & Agricultural Laboratory & Research Center PCL stock overvalued or undervalued in 2026?
As of Sep 24, 2026, AMARC trades below its calculated fair value: price 3.00 THB, fair value 9.47 THB, a gap of about +216% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AMARC?
No. The price is what the market pays today (3.00 THB); the fair value is what the company's own numbers justify (9.47 THB). For Asia Medical & Agricultural Laboratory & Research Center PCL the two are 6.47 THB per share apart. That gap is exactly why we show both numbers side by side.
How much is Asia Medical & Agricultural Laboratory & Research Center PCL worth?
The market values Asia Medical & Agricultural Laboratory & Research Center PCL at about 1.4B THB (market capitalisation, as of Sep 24, 2026). Per share that is 3.00 THB; our models calculate a fair value of 9.47 THB per share.
What do the bullish and bearish scenarios say about AMARC?
Our models span a range for Asia Medical & Agricultural Laboratory & Research Center PCL: cautious scenario 5.49 THB, base 9.47 THB, optimistic 14.49 THB per share (as of Sep 24, 2026, price 3.00 THB). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of AMARC?
Asia Medical & Agricultural Laboratory & Research Center PCL trades at a price-to-earnings ratio of 7.9 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 9.47 THB is built from several models across several years. Other multiples: P/B 2.4, P/S 2.8, EV/EBITDA 7.5.
How solid is the balance sheet of Asia Medical & Agricultural Laboratory & Research Center PCL (AMARC)?
Balance-sheet figures for Asia Medical & Agricultural Laboratory & Research Center PCL (as of Sep 24, 2026): return on equity 27.4%, debt of 0.12 per unit of equity. They feed the Quality Score of 80/100, which measures business quality independently of the share price.
How far is AMARC from its 52-week high?
Asia Medical & Agricultural Laboratory & Research Center PCL trades at 3.00 THB, about 39% below its 52-week high of 4.92 THB and 41% above the low of 2.12 THB (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 9.47 THB is for.
Which stocks are comparable to Asia Medical & Agricultural Laboratory & Research Center PCL?
From the same area (Technology) we also value Keysight Technologies, Inc, Garmin Ltd, Teledyne Technologies Incorporated, Chroma ATE Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Asia Medical & Agricultural Laboratory & Research Center PCL stock attractive at the current price?
The data as of Sep 24, 2026: price 3.00 THB, calculated fair value 9.47 THB (+216%), Quality Score 80/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AMARC calculated?
We run Asia Medical & Agricultural Laboratory & Research Center PCL through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 9.47 THB, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Asia Medical & Agricultural Laboratory & Research Center PCL currently trades 216 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Asia Medical & Agricultural Laboratory & Research Center PCL (AMARC)?
The closing price on Sep 24, 2026 was 3.00 THB. Our model-based fair value is 9.47 THB, about +216% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Asia Medical & Agricultural Laboratory & Research Center PCL right now?
The rarer combination: high quality (80/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case (5.49 THB). The market is more pessimistic than our downside scenario. The model range is unusually wide (5.49 THB to 14.49 THB). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Asia Medical & Agricultural Laboratory & Research Center PCL
How large is the market capitalisation of Asia Medical & Agricultural Laboratory & Research Center PCL (AMARC)?
The market capitalisation of Asia Medical & Agricultural Laboratory & Research Center PCL is 1.4B THB (≈ $42.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Asia Medical & Agricultural Laboratory & Research Center PCL (AMARC)?
The price-to-sales ratio of Asia Medical & Agricultural Laboratory & Research Center PCL is 2.55 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Asia Medical & Agricultural Laboratory & Research Center PCL (AMARC)?
Earnings per share at Asia Medical & Agricultural Laboratory & Research Center PCL are 0.3800 THB (price ÷ EPS = P/E 7.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Asia Medical & Agricultural Laboratory & Research Center PCL (AMARC)?
The dividend yield of Asia Medical & Agricultural Laboratory & Research Center PCL is 8.3% (payout 65.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Asia Medical & Agricultural Laboratory & Research Center PCL (AMARC)?
The net margin of Asia Medical & Agricultural Laboratory & Research Center PCL is 32.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Asia Medical & Agricultural Laboratory & Research Center PCL (AMARC)?
The return on equity (ROE) of Asia Medical & Agricultural Laboratory & Research Center PCL is 27.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Asia Medical & Agricultural Laboratory & Research Center PCL (AMARC)?
On an EBIT basis the return on assets of Asia Medical & Agricultural Laboratory & Research Center PCL is 8.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Asia Medical & Agricultural Laboratory & Research Center PCL (AMARC)?
The operating margin of Asia Medical & Agricultural Laboratory & Research Center PCL is 20.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Asia Medical & Agricultural Laboratory & Research Center PCL (AMARC)?
Revenue at Asia Medical & Agricultural Laboratory & Research Center PCL is growing +2.1% versus a year earlier (3y avg +23.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Asia Medical & Agricultural Laboratory & Research Center PCL (AMARC)?
Earnings per share at Asia Medical & Agricultural Laboratory & Research Center PCL are growing −2.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Asia Medical & Agricultural Laboratory & Research Center PCL (AMARC) hold?
Asia Medical & Agricultural Laboratory & Research Center PCL holds more cash than debt, 15.3M THB net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Asia Medical & Agricultural Laboratory & Research Center PCL in the live analysis
One click puts Asia Medical & Agricultural Laboratory & Research Center PCL on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
